XML 93 R80.htm IDEA: XBRL DOCUMENT v3.22.2
Organizational structure (Tables)
 12 Months Ended
Mar. 31, 2022
Interests in other entities [Abstract]  
Disclosure of interests in other entities [text block]
Dr. Reddy’s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries and joint ventures as of March 31, 2022: 
Name of the subsidiary/joint venture
  
Country of
Incorporation
  
Percentage of
Direct/Indirect Ownership
Interest
Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.
 
Malaysia
  
100%
(3)
Aurigene Discovery Technologies Limited
  
India
  
100%
Aurigene Pharmaceutical Services Limited (from September 16, 2019)
  
India
  
100%
(3)
beta Institut gemeinnützige GmbH
  
Germany
  
100%
(8)
betapharm Arzneimittel GmbH
 
Germany
  
100%
(8)
Cheminor Investments Limited
 
India
  
100%
Cheminor Employees Welfare Trust
  
India
  
Refer to below footnote
(15)
Chirotech Technology Limited
  
United Kingdom
  
100%
(2)(5)
Dr. Reddy’s Research Foundation
  
India
  
Refer to below footnote
(15)
Dr. Reddy's Employees ESOS Trust
 
India
  
Refer to below footnote
(15)
Dr. Reddy’s Farmaceutica Do Brasil Ltda.
 
Brazil
  
100%
Dr. Reddy’s Laboratories (EU) Limited
 
United Kingdom
  
100%
(10)
Dr. Reddy’s Laboratories (Proprietary) Limited
 
South Africa
  
100%
(10)
Dr. Reddy’s Laboratories (UK) Limited
 
United Kingdom
  
100%
(5)
Dr. Reddy’s Laboratories Canada, Inc.
 
Canada
  
100%
(10)
Dr. Reddy's Laboratories Chile SPA.
 
Chile
  
100%
(10)
Dr. Reddy’s Laboratories, Inc.
  
U.S.A.
  
100%
(10)
Dr. Reddy’s Laboratories Japan KK
  
Japan
  
100%
(10)
Dr. Reddy’s Laboratories Kazakhstan LLP
 
Kazakhstan
  
100%
(10)
Dr. Reddy’s Laboratories Louisiana, LLC
 
U.S.A.
  
100%
(6)
Dr. Reddy’s Laboratories Malaysia Sdn. Bhd.
 
Malaysia
  
100%
(10)
Dr. Reddy’s Laboratories New York, LLC
 
U.S.A.
  
100%
(1)
Dr. Reddy’s Laboratories Philippines Inc.
   Philippines  
100%
(10)
Dr. Reddy’s Laboratories Romania S.R.L.
 
Romania
  
100%
(10)
Dr. Reddy’s Laboratories SA
  
Switzerland
  
100%
Dr. Reddy’s Laboratories Taiwan Limited
  Taiwan  
100%
(10)
Dr. Reddy’s Laboratories (Thailand) Limited
  Thailand  
100%
(10)
Dr. Reddy’s Laboratories, LLC
 
Ukraine
  
100%
(10)
Dr. Reddy’s New Zealand Limited
  
New Zealand
  
100%
(10)
Dr. Reddy’s S.R.L.
  
Italy
  
100%
(11)
Dr. Reddy’s Bio-Sciences Limited
  India  
100%
Dr. Reddy’s Laboratories (Australia) Pty. Limited
  Australia  
100%
(10)
Dr. Reddy’s Laboratories S.A.S.
  Colombia  
100%
(10)
Dr. Reddy’s Research and Development B.V.
  Netherlands  
100%
(12)
Dr. Reddy’s Venezuela, C.A.
  Venezuela  
100%
(10)
Dr. Reddy’s (WUXI) Pharmaceutical Company Limited
 
China
  
100%
(2)(10)
Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited (from August 19, 2020)
  
China
  
100%
(10)
DRES Energy Private Limited
 
India
  
26%
(14)
DRL Impex Limited
  
India
  
100%
(13)
Dr. Reddy’s Laboratories B.V.
   Netherlands  
100%
(12)
Dr. Reddy’s Formulations Limited (from March 11, 2021)
  
India
  
100%
Idea2Enterprises (India) Private Limited
  
India
  
100%
Imperial Credit Private Limited
 
India
  
100%
Industrias Quimicas Falcon de Mexico, S.A. de CV
  
Mexico
  
100%
Kunshan Rotam Reddy Pharmaceutical Co. Limited
 
China
  
51.33%
(4)
Lacock Holdings Limited
  
Cyprus
  
100%
(10)
Nimbus Health, GmbH (from February 24, 2022)
   Germany  
100%
(8)
Dr. Reddy’s Laboratories LLC
   Russia  
100%
(10)
DRS LLC
   Russia  
100%
(9)

 
Name of the subsidiary/joint venture
  
Country of
Incorporation
  
Percentage of
Direct/Indirect Ownership
Interest
Promius Pharma, LLC
   U.S.A.  
100%
(6)
Reddy Holding GmbH
  Germany  
100%
(10)
Reddy Netherlands B.V.
  Netherlands  
100%
(10)
Reddy Pharma Iberia S.A.U.
   Spain  
100%
(10)
Reddy Pharma Italia S.R.L.
  Italy  
100%
(7)
Reddy Pharma SAS
  France  
100%
(10)
Svaas Wellness Limited
  India  
100%
Aurigene Discovery Technologies, Inc.
 
 U.S.A.
 
100%
(3)(16)
DRANU LLC
 
 U.S.A.
 
50%
(17)
 
(1)
 Indirectly owned through Dr. Reddy’s Laboratories, Inc. (from October 29, 2020), formerly a subsidiary of Dr. Reddy’s Laboratories SA. Also, conversion from corporation to limited liability company is effective October 30, 2020.
(2)
 Entity under liquidation.
(3)
 Indirectly owned through Aurigene Discovery Technologies Limited.
(4)
 Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as per Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company’s financial statements.
(5)
 Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited.
(6)
 Indirectly owned through Dr. Reddy’s Laboratories Inc.
(7)
 Indirectly owned through Lacock Holdings Limited.
(8)
 Indirectly owned through Reddy Holding GmbH.
(9)
 Indirectly owned through Dr. Reddy’s Laboratories LLC, Russia.
(10)
 Indirectly owned through Dr. Reddy’s Laboratories SA.
(11)
 Indirectly owned through Reddy Pharma Italia S.R.L.
(12)
 Indirectly owned through Reddy Netherlands B.V.
(13)
 Indirectly owned through Idea2Enterprises (India) Pvt. Limited.
(14)
 Accounted in accordance with IFRS 11,
“Joint Arrangements”
.
(15)
 The Company does not have any equity interests in this entity, but has significant influence or control over it.
(16)
Liquidated on March 23, 2022.
(17)
Pursuant to the sale of the membership interests in DRANU, LLC, it ceased to be a joint venture effective March 31, 2021.